ClinicalTrials.gg
CompletedNCT05516979EXPANDUpdated Nov 7, 2023

A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment

A Phase 2 interventional study of 100 mg AP1189 and Placebo in Rheumatoid Arthritis, sponsored by SynAct Pharma Aps. Completed at 1 site in Moldova, Republic of. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-11-07.

Sponsored by SynAct Pharma Aps · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Arthritis, Rheumatoid with a site in Moldova, Republic of — none open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Moldova, Republic of.

Enrollment
13th of 26
127 · median 126
Started
2022
with 1 other
Phase 2
17 of 26
none open now
Registered
24th of 26
by date
Lead sponsor
2 of 26
SynAct Pharma Aps

Among the 26 studies in Arthritis, Rheumatoid with a site in Moldova, Republic of, this one is the 13th largest by enrollment, is one of 2 that started in 2022, is one of 17 in phase 2, and was the 24th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 26 studies in Arthritis, Rheumatoid with a site in Moldova, Republic of is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies in Arthritis, Rheumatoid with a site in Moldova, Republic of as a file.
02

Study summary

The study is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of 12 weeks daily treatment with 100 mg AP1189 in RA patients who are to start up-titration with methotrexate (MTX).

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Confirmed diagnosis of RA according to the 2010 ACR/EULAR RA classification criteria and are ACR class I-III
  • ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts).
  • Candidate for MTX treatment
  • Is about to begin treatment with MTX
  • Must meet at least one of the following parameters at Screening:

    1. positive result for anti-CCP or RF
    2. Serum CRP ≥ 6 mg/L
  • Highly active RA (CDAI > 22) at screening and baseline
  • Negative QuantiFERON-in-Tube test (QFG-IT)
  • Females of must use of highly effective method

Main Exclusion Criteria:

  • Major surgery (including joint operation) within 8 weeks prior to screening or planned surgery within 1 month following randomization
  • Rheumatic disease other than RA, including systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), scleroderma, polymyositis, or significant systemic involvement secondary to RA. Sjögren's syndrome with RA is allowable
  • Prior history of or current inflammatory joint disease other than RA
  • Subjects with fibromyalgia
  • Use of hydroxychloroquine within 4 weeks prior the Screening Visit
  • Initiation of, or change in existing NSAID treatment within 2 weeks prior to the baseline visit
  • except inhaled or nasal formulations for seasonal allergy or asthma are prohibited within 2 weeks prior to screening
  • Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease
  • Have prior renal transplant, current renal dialysis, or severe renal insufficiency
  • Uncontrolled disease states, such as asthma, psoriasis, or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids
  • Evidence of active malignant disease (except basal cell carcinoma of the skin that has been excised and cured)
  • Neuropathies or other painful conditions that might interfere with pain evaluation
  • Body weight of >150 kg
  • positive and/or Anti-HBc with sign of current infection.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    100 mg AP1189

    Treatment period of 12 weeks given as 1 tablet daily

    Drug: 100 mg AP1189

  • Placebo comparator
    Placebo

    Treatment period of 12 weeks given as 1 tablet daily

    Drug: Placebo

Interventions

  • AP1189 tablets for oral use

    Also known as: AP1189 tablets for oral use

  • DrugPlacebo

    Matching placebo for oral use

06

What researchers measure

Primary outcomes

  1. Number of reported AEs

    Evaluation of the safety and tolerability of AP1189 on the number and severity of reported Adverse Events, compared with placebo

    Time frame: 12 weeks

  2. Change in ACR20

    The change in American College of Rheumatology 20% (ACR20) compared to baseline

    Time frame: 12 weeks

Secondary outcomes

  1. Change in ACR50

    The change in American College of Rheumatology 50% (ACR50) compared to baseline

    Time frame: 12 weeks

  2. Change in ACR70

    The change in American College of Rheumatology 70% (ACR70) compared to baseline

    Time frame: 12 weeks

  3. Change in (CDAI)

    The change Clinical Disease Activity Index (CDAI) compared to baseline

    Time frame: 12 weeks

  4. Change in DAS-28

    The change in DAS-28, based on a CRP value, compare to baseline

    Time frame: 12 weeks

07

Study locations

1 site
  • Timofei Mosneaga Republican Clinical Hospital
    Chișinău, Moldova, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Jul 2023, 9 months.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 9 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2022
First posted
Aug 26, 2022
StartActual
Sep 26, 2022
Primary completionActual
Jul 20, 2023
CompletionActual
Jul 20, 2023
Last update
Nov 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05516979
Lead sponsor
SynAct Pharma Aps
Collaborators
NBCD A/S
Responsible party
Sponsor
First posted
Aug 26, 2022
Start date
Sep 26, 2022
Primary completion
Jul 20, 2023
Completion
Jul 20, 2023
Last update
Nov 7, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Resomelagon acetate

Start the discussion